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ABSTRACT 
Women with antiphospholipid syndrome (APS) have circulating antiphospholipid 
antibodies (aPL) and are at risk for recurrent pregnancy loss and late pregnancy 
complications due placental dysfunction. Recent research has demonstrated that aPL 
directly alter human first trimester trophoblast function by up-regulating 
inflammatory cytokines, limiting cell migration, and altering angiogenic factor 
production. Due to their anti-inflammatory properties, Statins have been tested both 
in vitro, using human trophoblast, and in vivo, using a mouse model, for the 
treatment of APS-associated pregnancy complications and preeclampsia.  In vivo 
mouse studies showed that statins prevent aPL- mediated fetal loss, whereas in vitro 
human studies suggest that statins, like pravastatin may compromise normal 
trophoblast function and viability. Therefore, the objective of this study was to test 
the hypothesis that pravastatin prevents the effects of aPL-on human first trimester 
trophoblast function. The human first trimester trophoblast cell line, HTR8, and first 
trimester trophoblast primary cultures were incubated with or without an aPL in the 
presence or absence of pravastatin. Cytokine and angiogenic factor secretion were 
measured by ELISA and multiplex analysis. Cell migration was measured using a 
colorimetric two-chamber migration assay. Pravastatin significantly augmented the 
aPL-induced up-regulation of IL-8, IL-1 and sEndoglin secretion by HTR8 cells, but 
had no effect on aPL-induced up-regulation of VEGF, PlGF and GRO-. 
Furthermore, pravastatin alone limited basal HTR8 cell migration, and did not 
mitigate the adverse effect of aPL on trophoblast migration. However, Pravastatin 
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had no effect on aPL-mediated changes in primary first trimester trophoblast 
function. These findings demonstrate that pravastatin does not prevent the effects of 
aPL antibody on first trimester trophoblast cell function, and so may not be 
beneficial as a therapeutic for pregnant APS patients. However, it did not have any 
negative effects on basal primary cell function and, therefore, may be safe to use in 
patients at high risk for preeclampsia.  
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 6 
INTRODUCTION 
 
Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a systemic 
autoimmune disease that is diagnosed when a person with laboratory evidence of 
persistent circulating antiphospholipid (aPL) antibody presents clinically with 
vascular thrombosis and/or pregnancy morbidity [1, 2, 3, 4]. Persistent circulating 
aPL refers to the presence of aPL on at least two separate occasions that are at least 6 
weeks apart [1]. The pregnancy morbidities in pregnant APS patients vary and 
include recurrent fetal loss (rate can be up to 90% when no specific treatment is 
given [5]), as well as late term complications such as preeclampsia, HELLP 
Syndrome (Hemolytic anemia, Elevated Liver enzymes and Low Platelet count), 
premature birth and intrauterine growth restriction (IUGR) [6]. However, the 
pregnancy morbidities required for the diagnosis of APS are history of unexplained 
recurrent fetal loss, or premature birth secondary to preeclampsia or any other 
feature suggestive of placental insufficiency [2]. In addition to obstetric 
complications, APS patients in general are at significant risk of vascular thrombosis; 
hence it is an alternative clinical requirement for diagnosis of the disease. In fact, 
overall, thrombotic complications are the main source of complications in APS 
patients [7] as they are 3-10 times more likely to have thrombosis than people 
without aPL antibodies [1]. Vascular thrombosis can be both arterial (especially 
cerebral vessels) and venous (especially the deep veins of the lower extremities). 
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APS is caused by a group of heterogenous autoantibodies which, although they are 
called antiphospholipid antibodies, actually bind to phospholipid-binding proteins 
such as Annexin V, Protein C, Prothombin and beta 2-glycoprotein 1 (2GPI) [2, 3, 8]. 
The clinically significant aPL used in the diagnosis of APS are either ELISA-detected 
IgG or IgM anticardiolipin (aCL) and/or anti-2GPI antibodies or a functional assay 
for lupus antigoagulant (LA) that determines its anticoagulant activity against 2GPI 
and prothrombin [2]. The LA test is most commonly used for diagnosis. These 
antibodies are present in 7- 25% of women with recurrent fetal loss [2, 3]. Though 
lupus anticoagulant is one of the antibodies used in diagnosis of APS, and one third 
of patients with systemic lupus erythematous (SLE) have aPL and may in fact meet 
the criteria for APS, it is important to note that SLE is a separate entity from APS; 
there are specific and different set of criteria for diagnosis of SLE [9]. APS can be 
present in the absence of any other autoimmune disease (called primary APS in such 
scenario), or in the presence of another autoimmune disease such as SLE, in which 
case it is designated as secondary APS.   
 
Of the known phospholipid-binding proteins, 2GPI is the most clinically significant 
in the pathology of APS and all the afore mentioned aPL antibodies (LA, aCL and 
anti-2GPI) can bind to it. However, one can have LA and aCL without 2GPI 
activity because LA can also bind to prothrombin, and while 2GPI is a cofactor for 
binding of aCL in APS, there is also 2GPI-independent aCL that is associated with 
infectious process [2]. Beta 2 glycoprotein 1 is a highly glycosylated protein with a 
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lysine-rich domain that interacts with and is immobilized when it binds to 
negatively charged membrane phospholipids such cardiolipin and phosphatidyl 
serine [2, 8]. The formation of an aPL-2GPI complex increases the affinity of 2GPI 
for membrane phospholipid [2].  
 
While most cells will only bind exogenous β2GPI on their cell surface under 
pathologic, stimulatory or apoptotic conditions, when the inner negatively charged 
phospholipids become exposed onto the outer leaflet of the plasma membrane [8, 10, 
11, 12], the trophoblast (cells of the placenta) is unusual in that it normally expresses 
these anionic phospholipids on its cell surface [8, 13, 14, 15]. This is due to 
trophoblast cell’s high level of tissue remodeling involving high levels of 
proliferation and differentiation as part of normal placentation [8]. For review, 
normal placentation begins with the blastocyst adhering to the uterine wall. This is 
followed by invasion of the endometrium by a subset of trophoblast cells called 
cytotrophoblasts, the trophoblast stem cell, which undergoing proliferation to 
regenerate the functional cells that constitute the placenta [16]. These 
cytotrophoblasts can take two differentiation routes: 1) to undergo fusion to form 
the outer syncytiotrophoblast layer of the placenta; and 2) invading deep into the 
maternal decidual tissue, and here differentiating into extravillous trophoblast cells. 
These extravillous trophoblast cells then proceed to invade the maternal spiral 
arteries and remodel these vessels, differentiating into endovascular trophoblast 
cells and replacing the maternal endothelial cells. This transformation of the 
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maternal vasculature results in increased blood flow into the placental intervillous 
space.  The presence of anionic phospholipids on the outer leaflet of the trophoblasts 
has been linked to their abilities to undergo their normal functions, including fusion 
to form the syncytium [2, 15, 17]. Therefore due to the presence of anionic 
phospholipids on its outer leaflet of the cell membrane, the trophoblast can bind 
exogenous β2GPI on its cell surface under normal physiological conditions. 
Additionally, trophoblast normally produces its own 2GPI, and in vivo, there is 
evidence that β2GPI localizes to the surface of the extravillous trophoblast cells that 
invade the decidua, and to the syncytiotrophoblast cells that are in direct contact 
with maternal blood [8]. These reasons explain the tropism of aPL for the placenta 
[2, 4, 8] and is further supported by the laboratory finding that passive transfer of 
human aPL into pregnant mice leads to its disappearance from peripheral 
circulation and accumulation in the placenta [2]. The fact that the placenta is a major 
target for aPL partly explains why pregnancy complications associated with altered 
placental development and function occur in women with APS.  
 
Apart from impairing trophoblast fusion and differentiation into giant 
multinucleated cells [2], binding of aPL can decrease the production of normal 
pregnancy hormone production [2, 12] and alter cytokine production [2,8]. These can 
partially explain the observation of insufficient placentation (evidenced by reduced 
trophoblast invasion) and limited spiral artery transformation in APS, similar to 
what is seen in preeclampsia [8, 18]. Further, the process of decidualization in a 
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normal pregnancy includes recruitment of specialized population of maternal 
immune cells, which eventually compose about 70% of cells in the uterus during 
pregnancy [19]. These cells, consisting of specialized natural killer cells (~75%), some 
monocytes and dendritic cells (~15%) and regulatory T cells (~15), are not 
inflammatory and do not participate in cellular cytotoxicity; rather, they play an 
immunoregulatory role, which is essential for a successful pregnancy as they are 
able to coexist with foreign cells and enhance maternal tolerance [19]. Unlike normal 
in normal pregnancy, the decidua in APS patients has inflammatory immune cell 
(macrophages and neutrophils) infiltration [20, 21, 22].  
 
Given the propensity for vascular thrombosis in APS patients, pregnancy failure in 
APS was initially attributed to thrombosis at the maternal fetal interface [3, 8]. Hence 
the original method of therapy for the high rates of miscarriages was anticoagulation 
with heparin with or without aspirin. To date, the standard of care for obstetrical 
APS includes either low dose aspirin before conception and throughout pregnancy 
up to 4 months postpartum, or low molecular weight heparin (LMWH) plus low 
dose ASA during pregnancy [2]. However, both clinical observations and 
experimental findings have called this basis of treatment into question. Histological 
studies have shown that intravascular or intervillous blood clots are not commonly 
found in samples of placentas from APS patients with miscarriage [23]. Further, 
clinically, while treatment with heparin increases live birth rates, it does not prevent 
late term complications of APS such as preeclampsia [3, 5, 24, 25, 26]. Moreover, its 
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efficacy is controversial and is yet to be confirmed in a randomized controlled trial 
[27, 28]. Hence, despite treatment, pregnant APS patients remain high-risk obstetric 
cases throughout gestation. Additionally, studies have raised questions about the 
safety of these therapeutics, in particular low molecular weight heparin (LMWH). 
Carroll et al found that in vitro, LMWH independently up-regulated first trimester 
trophoblast expression of the potent anti-angiogenic factor, soluble fms-like tyrosine 
(sFlt) [29], which is associated with preeclampsia [30, 31, 32, 33, 34]. Other 
researchers have reported this finding both in vitro [35, 36] and in vivo in pregnant 
women treated with heparin [35, 37]. Moreover, Han et al showed that LMWH also 
induced an increase in basal GRO secretion by first trimester trophoblasts [36]. 
These observations and findings prompted further investigation into the true 
pathologic mechanism(s) involved in APS, as this would direct better the 
identification of novel therapeutics and thus, the management of APS patients.  
 
Similar to what is observed in endothelial cells, where binding of aPL to 2GPI on 
the surface of the endothelial cells leads to induction of a pro-inflammatory state [1, 
38], recent studies now strongly demonstrate a primary role for inflammation at the 
maternal-fetal interface, rather than thrombosis, in APS-associated pregnancy 
pathology. Studies have shown histological signs of acute and chronic inflammation 
in the placental beds of samples of miscarriages in APS patients [21, 22]. 
Additionally, studies with animal models of APS have shown local and/or systemic 
elevation of inflammatory markers such as TNF and tissue factor level [20, 39]. 
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Further, complement C3 deposition in the decidua has been observed, and blocking 
of the complement pathway or tissue factor prevented aPL-mediated pregnancy 
failure and associated inflammation [40, 41,42, 43]. And, as mentioned earlier, both 
placentas from animal models of APS and human tissues have shown inflammatory 
immune cell infiltration [20, 21]. Most recently, studies from the Abrahams lab, have 
shown that aPL markedly enhances human first trimester trophoblast production of 
pro-inflammatory cytokines, such as interleukin 8 (IL 8), Interleukin 1 (IL1-), 
monocyte chemoattractant protein 1 (MCP-1) and GRO alpha (GRO), via 
TLR4/MyD88 dependent pathway [44]. Further, the lab has illustrated that aPL 
inhibit trophoblasts constitutional secretion of interleukin 6 (IL 6), is a cytokine that 
is associated with trophoblast invasiveness [45, 46], leading to decreased STAT3 
activity and subsequently trophoblast migration [47]. Indeed, IL-6 deficient mice 
exhibit impaired implantation and reduced litter size [45, 46]. Therefore, the 
trophoblast expression of IL 6 is important for normal trophoblast migration. Hence 
impairment of IL-6 production by aPL, may lead to failure of the trophoblast to 
effectively perform one of its basic functions in pregnancy. Also, aPL perturbs 
angiogenic factor profile by up-regulating vascular endothelial growth factor 
(VEGF), placental growth factor (PlGF) and soluble endoglin [29]. These findings, 
combined with aforementioned in vivo animal studies, plus the dearth of thrombosis 
in the histology of placenta from miscarriages in APS patients, has led to a 
widespread acceptance that non-thrombotic, inflammatory mechanisms are the 
main causes of defective placentation in APS. Even the observed partial efficacy of 
 13 
heparin supports this notion as studies have shown that heparin possesses anti-
inflammatory property due to its ability to inhibit complement activity [3, 41]. In one 
study, treatment of pregnant APS mice with pure anticoagulants such as 
fondaparinux and hirudin did not prevent aPL-induced pregnancy loss, whereas 
treatment with unfractionated heparin and low molecular weight heparin 
suppressed complement activity and increased live birth rate [41]. Hence the 
observed efficacy of heparin is likely due to its anti-inflammatory properties, not its 
anticoagulant property. However, heparin cannot reverse all effects of aPL on 
trophoblast function and as aforementioned, might exacerbate some [29, 36]. Hence, 
there continues to be growing interest towards finding alternative treatments for the 
pregnant APS patients.  
 
In the pursuit of better treatment therapy, 143-hydroxy-3-methyl-glutaryl-CoA 
(HMG-CoA) reductase inhibitors (statins) have been proposed for use in preventing 
APS-associated pregnancy complications. In addition to lowering cholesterol, statins 
have been shown to possess anti-inflammatory properties. The anti-inflammatory 
properties of statins, as observed mostly in atherogenesis, include: a decrease in 
immune cell infiltration of tissues; a decrease in adhesion molecules such as ICAM-
1, VCAM-1, E-selectin and P-selectin; a decrease in chemoattractant proteins such as 
MCP-1 and IL-8; a decrease in pro-inflammatory transcription factors such as NFB; 
a decrease in pro-inflammatory enzymes such as COX-2; a decrease in pro-
inflammatory cytokines such as TNF, IL-1, IL-6; and a decrease in inflammatory 
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serum markers such as CRP [48, 49]. Even though statins are currently 
contraindicated in pregnancy due to risk of birth defects [50], the proposal for its use 
in APS has been based on the finding that pravastatin can prevent fetal loss in aPL-
treated mice [51]. However, the reported benefit of pravastatin in mouse model of 
APS has yet to be confirmed in a human model of APS.  Moreover, other studies 
have reported that statins negatively affect human first trimester trophoblast by 
decreasing migration and proliferation, and inducing apoptosis [52, 53, 54].  
Therefore, in light of these conflicting data, we decided to test the main hypothesis 
that pravastatin could prevent the effects of aPL on the trophoblast without 
affecting basal trophoblast function. Thus, the objective of this current study was 
to determine whether pravastatin could be used for the treatment of aPL-mediated 
pregnancy complications. In order to test this, specific aims of this project were to 
investigate:  
Aim 1: The effects of pravastatin on human first trimester trophoblast cell viability 
Aim 2: The effects of pravastatin on human first trimester trophoblast cytokine and 
angiogenic factor secretion in the absence and presence of aPL. 
Aim 3: The effects of pravastatin on human first trimester trophoblast cell migration 
the absence and presence of aPL. 
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MATERIALS AND METHODS 
 
Source and Maintenance of Trophoblast cells 
The human first trimester extravillous trophoblast cell line, HTR8, and primary 
trophoblast cultures isolated from first trimester placentas (8-12wks gestation) were 
used in these studies. The HTR8 cells, immortalized by SV40 [55], were a gift to the 
lab from Dr. Charles Graham (Queens University, Kingston, ON, Canada).  
 
HTR8 cells were cultured in growth media, prepared by supplementing RPMI 1640 
media (from Gibco) with 10% fetal bovine serum, 0.01% of 10mM Hepes, 0.01% of 
0.1mM MEM non-essential amino acids, 0.01% 1mM sodium pyruvate, and 0.01% of 
100nm penicillin/streptomycin. The cells were grown at 37˚C/5% CO2 in a sterile 
75cm2 polystyrene cell culture flask. When fully confluent, cells were split and then 
either plated for experiments, froze in liquid nitrogen for future lab work or 
maintained by continued culture.  
To split confluent cells for an experiment, 3-5ml of 0.05% Trypsin was added in the 
culture flask containing the cells. Trypsin was then activated by brief incubation of 
the cells at 37˚C until the cells had detached. Equal volume of growth media was 
added and the mixture transferred to a sterile 10ml polypropylene conical tube, 
centrifuged at 21˚C at 3000rpm at room temperature for 10mins and the pellet then 
re-suspended in 5-10ml of growth media. Cells were then counted and plated for 
experimentation as described below.  
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For primary cultures, first trimester placentas were obtained from elective 
terminations of normal pregnancies performed at Yale-New Haven Hospital. The 
use of patients samples was approved by Yale University's Human Investigation 
Committee. Ms. Mulla prepared tissue specimens as follows: Cells were washed 
with cold Hanks Balanced Salt Solution to remove excess blood. They were then 
scraped from the membranes, transferred to trypsin-EDTA digestion buffer and 
incubated at 37˚C for 40 minutes with shaking. The mixture was then passed 
through a nylon strainer and then layered over Lymphocyte Separation Media and 
centrifuged at 2000rpm for 25 minutes. The cellular interface containing the 
trophoblast cells was collected and re-suspended in D-MEM with D-valine 
supplemented with 10% normal human serum and cultured in 5% CO2 at 37˚C.  
 
Antiphospholipid antibodies 
The mouse IgG1 anti-human 2GPI monoclonal Ab (mAb), IIC5, was used in these 
studies. This antibody was produced by Larry W. Chamley (department of 
Obstetrics and Gynecology, University of Auckland, New Zealand), under sterile 
conditions, and was filter-sterilized prior to use. IIC5 was cloned from mice 
immunized with purified human 2GPI, and has been previously characterized [56]. 
Like human aPL, IIC5 binds 2GPI, but only when it is immobilized on a suitable 
negatively charged surface, such the phospholipids, cardiolipin, phosphatidyl 
serine, or irradiated polystyrene [57]. IIC5 binds to first trimester trophoblast cells 
 17 
and similar to patient-derived polyclonal aPL, it alters trophoblast function by 
inducing pro-inflammatory cytokine expression and perturbing angiogenic factor 
balance [29, 44].  
 
Cell viability studies 
Trophoblast cell viability was determined using the CellTiter 96 viability assay. Cells 
were plated in wells of a 96-well plate at 1x104 cells per well in growth media, at 
total volume of 100L, and cultured at 5% CO2 and 37˚C.When cells became 70% 
confluent media was replaced with 50L of serum-free Opti-MEM media 
(Invitrogen), and cultured for another 4hrs.  Treatments were prepared at double the 
target concentrations and 50L of treatments were added to the wells, bringing 
down the treatments to the final concentrations of CPT at 4M and pravastatin at 
0.1, 1, 2.5 and 5g/ml. All treatments were prepared in Opti-MEM. Cells were then 
incubated for 72hrs at 37˚C and afterwards, 20L CellTiter 96TM substrate was added 
to all wells. Cells were the incubated for an additional 2hrs at 37°C and optical 
densities were read at 490 nm. All samples were assayed in triplicate, and cell 
viability was presented as a percentage of the untreated control.  
 
Cytokine and angiogenic factor secretion studies 
Cytokine and angiogenic factor secretion were assessed using enzyme linked 
immunosorbent assay (ELISA) and multiplex analysis. Prior to this, HTR8 
trophoblast cells were plated at 6 x 104cells/ml in total volume of 2ml of growth 
 18 
media, in sterile 35mm petri dishes and cultured in growth media in similar 
conditions as above. When the cells were 70% confluent, the growth media was 
replaced with 2ml of OptiMEM and cells incubated for 4hrs at 37°C. OptiMEM was 
then replaced with treatments that consisted of IIC5 (aPL) at 20g/ml (in OptiMEM) 
in the presence and absence of pravastatin at either 0.5 or 2.5g /ml in OptiMEM. 
After 72 hours at 37°C, cell-free supernatants were collected by centrifugation at 
2000rpm at 4C for 5 minutes and stored at -80˚C until analysis was performed.  
 
For primary human first trimester trophoblast, the cells had heterogeneous growth 
rates since they were collected from different patient samples. As such, when plated, 
the cells in different plates attained 70% and 100% confluence at different times. 
Additionally, since we cannot culture them as long as the immortalized cell lines, we 
performed the experiments as soon as some of the petri dishes had 70% confluent 
cells. Therefore following treatments, just as in the case of HTR8 cells, and collection 
of supernatants, the cells were lysed and the total proteins collected. Bicinconinic 
assay (BCA) analysis was done to normalize the protein levels in the different 
treatment groups and to appropriately interpret the ELISA results. Total protein, 
was collected thus: After collecting the supernatant cold 1xPBS was added to the 
dishes and cells scraped off the dish using an autoclaved cell scraper. The mixture 
was then transferred to 15ml conical tube and centrifuged at 1500rpm for 10mins at 
4C. The pellet was re-suspended with 50L of lysis buffer (containing 0.02% PIC 
and PMSF), vortexed and incubated on ice for 20mins. Afterwards, the lysate was 
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centrifuged at 13000rpm for 15mins at 4C and supernatant stored at -40C until 
ready for BCA assay. 
At the time of analysis of supernatants from either HTR8 cells or primary 
trophoblasts, supernatants were thawed at room temperature and evaluated the 
concentrations of interleukin 8 (IL-8), vascular endothelial growth factor (VEGF), 
placenta growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble 
Endoglin (sEndoglin) using R&D systems ELISA kits and following the 
manufacturer’s instructions. The levels of IL-8, IL-1, GRO- and VEGF were also 
determined by multiplex analysis of the supernatants using the BioPLex assay with 
detection and analysis using the Luminex 100 IS system.  
 
Cell migration studies 
To assess trophoblast migration, a two chamber colorimetric assay was employed. 
The top chambers were made of 8µm pore size cell culture inserts, while the lower 
chambers were 24-well tissue culture plates. The lower chamber was filled with 
800µL of OPtiMEM and the top chamber was seeded with 1x105cells HTR8 cells, 
which were suspended in 200µL of treatments (media alone, aPL, pravastatin, or 
both). Following a 48hr incubation, inserts were removed and trophoblast migration 
across the membrane was determined using the QCM 24-Well Colorimetric Cell 
Migration assay according to the manufacturer’s direction (Chemicon International).  
Briefly, the filters on the top chamber was removed and transferred into wells 
containing 250l of cell stain. This process stains the migrated cells, which were 
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trapped in the pores of the filter, to stain. Afterwards, excess stain was removed by 
dipping the bottom of the filter into a beaker of distilled water and transferring filter 
into a clean well. of extraction buffer was then added to the wells and cells left 
to gently rock at 1.5rpm at room temperature for 15mins. of the resulting 
colored mixture was transferred to a 96-well plate and optical densities read in 
triplicate at 560 nm. A 100% migration control consisted of 1 x 105 HTR8 cells placed 
directly in the 24-well plate without any insert. Observed optical density values 
were measured using a BioRad plate reader, and were compared to the 100% 
migration control to determine the relative percent migration.  
 
Statistics 
All experiments were performed at least three times. I produced all of the data 
involving the HTR8 cell lines (cell viability, cytokine and angiogenic factor studies, 
and migration studies) as well as two sets of data for primary trophoblasts cell 
viability studies and one set of data for IL-8 levels. Ms. Mulla obtained the 
remaining data for primary trophoblast viability studies, cytokine and angiogenic 
factor production in the presence of pravastatin. Similarly, with the help of Dr. 
Abrahams, I performed the statistical analysis for data for HTR8 cells while Dr. 
Abrahams performed the statistical analysis of data for the primary trophoblast 
cells. Data are expressed as mean ± standard deviation (S.D.) of pooled experiments. 
Statistical significance (p<0.05) was determined using either the one-way Anova 
with the Bonferroni correction, or the paired student’s t-test. 
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RESULTS 
 
Effects of pravastatin trophoblast viability  
Previous studies have reported that statins can prevent human trophoblast 
proliferation and induce trophoblast apoptosis [52]. Therefore, the first objective of 
this study was to determine the effects of pravastatin on trophoblast cell viability 
under our laboratory conditions. Thus, the HTR8 cell line and primary trophoblast 
cultures were treated for 72hrs with either no treatment (NT), camptothecin (CPT, 
4M), which serves as a positive control for cell death, or pravastatin at 0.1, 1, 2.5 or 
5 g/ml. As shown in Figure 1A, treatment with pravastatin at the highest dose of 
5g/ml significantly decreased the viability of the first trimester trophoblast cell 
line, HRT8, by 22.9 ± 33.1% (p<0.05). As expected our positive control, CPT, also 
significantly decreased HTR8 cell viability by 78%  4.8% (p<0.001). At the lower 
doses of pravastatin (0.1 – 2.5g/ml), there was no significant effect on HTR8 
trophoblast cell viability (Figure 1A). In contrast, pravastatin, at all doses, did not 
have any affect on the viability of primary human first trimester trophoblast cell 
(Figure 1B).  
 
 
 22 
  
 
Due to the effect of the high dose pravastatin on HRT8 cells, all subsequent 
experiments were performed at lower doses that did not affect cell viability. Thus, 
for all other experiments, a low dose of 0.5g/ml and a high dose of 2.5g/ml was 
used. 
 
 
Effects of Pravastatin on aPL-induced inflammation on trophoblasts.  
We have previously demonstrated that the mouse anti-human 2GPI mAb, IIC5, and 
patient-derived polyclonal aPL, with 2GPI activity, induce a human first trimester 
trophoblast inflammatory response by up-regulating the cell’s secretion of IL-8, IL-
1 and GRO- [36, 44].  Therefore, we investigated whether pravastatin could 
counter these effects of aPL. Thus HTR8 cells were treated for 72hrs with or without 
the anti-2GPI Ab, in the presence of either media, pravastatin at 0.5g/ml or 
pravastatin at 2.5g/ml after which IL-8, IL-1 and GRO- secretion was measured. 
As shown in figure 2A high and low doses of pravastatin had no significant effect on 
Figure 1: Effects of pravastatin on viability of human first trimester trophoblast cells after 
incubation for 72hrs. (A) HTR8 trophoblast cell line (B) primary human first trimester 
trophoblasts. *P<0.05; **P<0.001; NT = no treatment, CPT = 4M of camptothecin. 
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basal IL-8 or GRO- secretion by HTR8 cell lines, but did significantly elevate basal 
IL-1 at the high dose (NT groups in figure 2A). Surprisingly, the presence of 
pravastatin at both high and low doses significantly augmented the anti-2GPI mAb-
induced up-regulation of IL-8 secretion by HTR8 cells (anti-2GPI mAb groups in 
figure 2A). Additionally, low dose pravastatin significantly augmented the anti-
2GPI mAb up-regulation of IL-1 atin had no significant effect 
on the up-regulation of GRO- induced by the anti-2GPI mAb on HTR8 cells. 
 
 
 
Figure 2A: Pravastatin augments aPL-mediated secretion of IL-8, IL-1, and GRO by human first 
trimester trophoblast cell line, HTR8. Treatment groups received 20g/ml of anti-2GP1 mouse Ab (IIC5) 
and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for 72hrs. NT = No 
treatment; *P<0.05; **P< 0.01; a = P<0.05 relative to NT; b = P<0.01 relative to NT. 
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In order to validate our findings, we next tested whether pravastatin had similar 
effects on primary human first trimester trophoblasts. Interestingly, in contrast to 
our findings using the HTR8 cell line, neither high nor low dose pravastatin altered 
the basal cytokine production in primary human first trimester trophoblasts (figure 
2B). Also, pravastatin had no effect on the aPL-induced up-regulation of pro-
inflammatory cytokines, IL-8, IL-1 and GRO-, secreted by primary trophoblast 
cells (figure 2B).  
 
 
 
 
Figure 2B:  Effects of pravastatin on aPL -mediated secretion of IL-8, IL-1, and GRO by 
primary human first trimester trophoblast. Treatment groups received 20g/ml of anti-
2GP1 mouse Ab (IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were 
incubated for 72hrs. NT = No treatment; *P<0.05 and **P< 0.01 relative to NT. 
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Effects of pravastatin on aPL-induced anti-angiogenic factor response in 
trophoblasts.  
We have recently demonstrated that the mouse anti-2GPI mAb, IIC5, and patient-
derived polyclonal aPL, alter angiogenic factor profile by up-regulating human first 
trimester trophoblast cell secretion of VEGF, PlGF and soluble endoglin [29, 36]. 
Therefore, one of the objectives of this study was to determine whether pravastatin 
impacts these angiogenic factor alterations caused by aPL. To test this, HTR8 cells 
were treated for 72hrs with or without the anti-2GPI Ab, in the presence of either 
media, pravastatin at 0.5g/ml or pravastatin at 2.5g/ml after which VEGF, PlGF, 
soluble endoglin and sFlt-1 levels were measured. As shown in figure 3A, 
pravastatin alone had no effect on the basal production of VEGF, PlGF or sEndoglin 
by HTR8 cells (NT groups in Figure 3A). But, at the high dose of 2.5g/ml, basal 
sFlt-1 secretion was significantly increased (p <0.01). Consistent with our prior 
studies, treatment of HTR8 cells with anti-2GPI mAb led to up-regulation of VEGF, 
PlGF and soluble endoglin with down-regulation of sFlt-1. Pravastatin slightly, yet 
significantly, reduced the ability of the anti-2GPI mAb to increase HTR8 VEGF and 
PlGF secretion (anti-2GPI mAb groups in Figure 3A). However at both high and 
low doses, pravastatin significantly augmented anti-2GPI mAb-induced up-
regulation of sEndoglin secretion by HTR8 (p< 0.01 and p<0.05 respectively). 
 
Since we had observed differential effects of pravastatin on basal and aPL-mediated 
changes in pro-inflammatory cytokine secretion by HTR8 cells and primary 
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trophoblasts, we were curious about the effects of pravastatin on basal and aPL-
mediated changes in aniogenic factor secretion by primary human first trimester 
trophoblasts. Apart from a significant decrease in basal sEndoglin level, pravastatin 
did not alter basal angiogenic factor production by primary first trimester 
trophoblasts. Furthermore, similar to the pattern in pro-inflammatory cytokine 
production, pravastatin did not reverse any of the aPL-mediated changes in 
angiogenic factor profiles of primary human first trimester trophoblasts (figure 3B).  
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Figure 3A: Pravastatin augments aPL-induced up-regulation of soluble endoglin (sEndo) by human 
first trimester trophoblast cell lines, HTR8.  Treatment groups received 20g/ml of anti-2GP1 mouse 
Ab (IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for 72hrs. NT 
= No treatment; *P<0.05; **P< 0.01; a = P<0.05 relative to NT; b = P<0.01 relative to NT. 
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Pravastatin does not reverse aPL inhibition of trophoblast migration.  
In addition to inducing a pro-inflammatory and anti-angiogenic profile, anti-2GPI 
mAb limit first trimester trophoblast migration [47]. Since the ability to migrate is 
one of the essential functions of the trophoblast and impaired migration and 
invasion predisposes to fetal loss in APS, it was important to us to assess whether 
pravastatin could mitigate this impaired migration caused by aPL. Therefore, HTR8 
cells were treated for 48hrs with or without the anti-2GPI Ab, in the presence of 
either media, pravastatin at 0.5g/ml or pravastatin at 2.5g/ml after which cell 
migration was determined using colorimetric two-chamber migration assay. As 
Figure 3B: Figure 2B:  Effects of pravastatin on aPL-mediated secretion of angiogenic factors by 
primary human first trimester trophoblast. Treatment groups received 20g/ml of anti-2GP1 
mouse Ab (IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for 
72hrs. NT = No treatment; *P<0.05 and **P< 0.01 relative to NT. 
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shown in Figure 4, pravastatin alone at the low dose of 0.5g/ml slightly but 
significantly reduced basal HTR8 cell migration (p < 0.01). At either doses, 
pravastatin had no effect on the inhibition of trophoblast migration induced by the 
anti-2GPI mAb. 
 
 
 
 
 
 
 
 
 
 
Figure 4: Pravastatin did not reverse aPL-antibody mediated decrease in migration of human first 
trimester trophoblast cell line, HTR8. Treatment groups received 20g/ml of anti-2GP1 mouse Ab 
(IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for 72hrs. NT = 
No treatment; *P<0.05; **P< 0.01; a = P<0.05 relative to NT; b = P<0.01 relative to NT. 
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DISCUSSION 
 
The majority (about 90%) of fetal losses seen in APS patients occurs during the first 
trimester, usually before 14 weeks of gestation [5]. Since aPL are present at the time 
of implantation, this suggests that the pathology in obstetric APS may evolve during 
the first trimester of pregnancy, similar to what is thought for preeclampsia [58, 59]. 
Therefore, understanding this pathology as it occurs early in pregnancy would help 
in the prevention of both the fetal loss and later term complications in APS. For this 
reason, we have chosen to study APS pathology and the efficacy of novel 
therapeutics in vitro using first trimester trophoblast cells.  
 
While women with APS are routinely treated with LMWH during pregnancy, 
clinical and experimental studies have highlighted the potential lack of efficacy of 
this regimen, as well as potential problems resulting from the treatment [27, 28, 29, 
35, 36, 37]. Consequently, there is a need for alternative preventative strategies in the 
management of pregnant women with APS. Recent studies in mice have 
demonstrated that the statin, pravastatin, prevents the onset of symptoms of 
preeclampsia brought about either by the overexpression of the anti-angiogenic 
factor human sFlt-1 [32, 33, 34] or the genetic background [60, 61], suggesting that it 
could be beneficial in prevention of preeclampsia. 
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Preeclampsia is a common adverse pregnancy outcome in women with APS [6, 62, 
63]. In this patient population, it can have early-onset and particularly be severe 
leading to high rate of preterm delivery [62]. Furthermore, similar to what is seen in 
preeclampsia, the histology of the placenta in APS shows shallow invasion of the 
decidua by the trophoblast, as well as poor remodeling of maternal spiral arteries 
[16, 23]. However, the mechanism for this observed phenomenon is likely different 
from preeclampsia. In APS, there is premature stimulation of cytotrophoblast 
proliferation and syncytial fusion leading to depletion of cytotrophoblasts [16].  
Since the cytotrophoblast is the trophoblastic stem cell, there is ultimately reduced 
number of stem cell pool to form syncytiotrophoblasts (the most important 
component of materno-fetal barrier) and extravillous trophoblasts that invade the 
decidua and maternal vessels.  There is no consensus on the cause of the premature 
stimulation of cytotrophoblast proliferation but with the large body of literature 
showing inflammation in APS, inflammation could play a role in this observed 
phenomenon. Due to the similar end results in placental morphology, the 
association between preeclampsia and APS, and the noted anti-inflammatory 
properties statins, researchers have tested the efficacy of pravastatin in APS model.  
Pravastatin was shown to prevent aPL-mediated pregnancy loss in mice [51, 64]. 
These findings of the effects of pravastatin in mouse models of classical 
preeclampsia and APS have led to an interest in the use of statins to treat pregnancy 
complications, such as preeclampsia and those associated with APS [51, 64]. Indeed, 
a randomized placebo-controlled clinical trial on statins for the prevention of early-
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onset preeclampsia, Statins to Ameliorate Early Onset Pre-eclampsia (StAmP Trial), 
is currently underway [65]. Since the impact of statins have yet to be tested in a 
human model of aPL-associated pregnancy problems, and studies using normal 
human placental explants have raised concerns over the use of statins during 
pregnancy [52, 53, 54], we sought to determine whether statin could prevent aPL-
mediated effects using a human trophoblast in vitro system.   
 
We used pravastatin in our studies because it is the statin that has been shown to be 
least associated with risk of fetal anomaly due to low lipophilicity [66]; since it does 
not easily crossing the placenta, it is thought to remain on the maternal side of the 
placenta. Since the objective of this study was to find out whether pravastatin could 
be used for the treatment of aPL-mediated pregnancy complications, low diffusion 
through the placenta was an important feature as any favorable finding can be 
extrapolated to an in vivo human model without fear of damage to the fetus, while 
still potentially benefiting placentation by minimizing the inflammation at the 
maternal side of the placenta and countering the effects of aPL on the placenta. In 
addition to having low permeability through the placenta, pravastatin was used 
because it has been shown to have beneficial effects in previous experimental studies 
in mice [32, 33, 34, 51]. Based on prior studies using pravastatin [54] and other 
statins [52], we were able to select a dose range that we considered appropriate to 
address the question in this study. In our preliminary experiments we found that 
while pravastatin had no adverse effect on the viability of primary first trimester 
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trophoblast cultures, pravastatin at 5g/ml, reduced the viability of human first 
trimester trophoblast cell line HTR8, an observation also made by other groups 
using human first trimester placental explants [52, 54]. Hence, we used pravastatin 
at concentrations (0.5g/ml and 2.5g/ml) that did not induce cell death. At these 
lower doses, we found that pravastatin modestly enhanced sFlt-1 and IL-1 
secretion and reduced the migratory capacity of HTR8 trophoblast. Our findings are 
in keeping with the observation by others, demonstrating that statins reduce 
trophoblast cell migration and outgrowth from first trimester explant cultures [52, 
53]. 
 
We also failed to observe unequivocal beneficial effects of pravastatin on HTR8 
trophoblast exposed to the anti-2GPI mAb. Pravastatin was unable to prevent the 
up-regulation of the pro-inflammatory cytokines IL-8, IL-1, and GRO-; the 
induction of sEndoglin; or the reduction in cell migration upon exposure to aPL 
antibody. Pravastatin did, however, reduce aPL antibody-induced VEGF and PlGF 
secretion. While this reached significance, these effects were modest and unlikely to 
have physiological consequences. Moreover, this finding does not support the 
observation in the mouse model of preeclampsia where pravastatin increases PlGF 
expression [34].  
 
Where we did see a marked effect by pravastatin was in its ability to augment aPL-
induced secretion of IL-8, IL-1 and sEndoglin by the HTR8 trophoblast cell line. 
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Indeed studies using immune cells have shown that statins can enhance LPS-
induced inflammation, including IL-8 and IL-1 production [67, 68, 69]. Since aPL-
induced IL-8 and IL-1 is mediated by TLR4 [44], the mechanism by which 
pravastatin enhances the trophoblast inflammatory response to aPL may be similar. 
However, when the effect of pravastatin was tested using primary human first 
trimester trophoblast cultures, we found no positive or negative effects on either 
basal or aPL-stimulated cytokine and angiogenic factor production.  
 
The reason for the difference in observations between the trophoblast cell line and 
primary cells may be because the primary cultures are a more heterogeneous 
population. Alternatively, since we have observed similar effects of the aPL on both 
the primary trophoblast and the trophoblast cell line in our previous studies [29, 44], 
our results may indicate that pravastatin has differential effects on the two types of 
culture. Indeed, the augmentation of aPL-induced IL-1, IL-8 and sEndoglin 
secretion by pravastatin in the cell line may be a reflection of pravastatin's ability to 
slightly elevate the cell line's basal production of these factors; an observation not 
seen in the primary cultures.   
 
Based on our observations we can conclude that while pravastatin may not be 
overtly detrimental to the trophoblast in the absence of aPL in terms of cytokine and 
angiogenic factor production, alone it still might impair placental cell function by 
limiting migration, which is critical for normal placentation; and it fails to protect 
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the trophoblast from aPL effects. Thus, our findings might be taken to not support 
the use of pravastatin in APS patients. Why this is in contrast to the in vivo studies 
showing that pravastatin prevents aPL-induced pregnancy loss may simply be a 
consequence of species differences, with different pharmacokinetics in each species. 
Alternatively, it might be a result of methodology. In vivo, significant maternal 
blood flow to the villous tissues begins around weeks 10-12; before this, there is low 
oxygen concentration in the intervillous space and it enables trophoblast to rapidly 
proliferate while protected from free oxygen free radical [16].  This hypoxic 
condition is not represented in our experimental system as we performed our 
incubations at normoxic conditions. Therefore, another possibility for the differences 
between the cell types could be a result of the oxygen concentration used. 
Furthermore, in the mouse model of aPL-induced pregnancy failure, pravastatin 
was administered prior to aPL exposure, whereas in our in vitro model, trophoblast 
cells were treated simultaneously with aPL and pravastatin. Moreover, the mouse 
model explains the pathogenesis of APS-associated pregnancy failure and the 
success of pravastatin in preventing this is based on its ability to prevent aPL-
induced neutrophil tissue factor and PAR-2 expression [51, 64], rather than the direct 
effects of aPL on the trophoblast, as in our model [29, 36, 44, 47]. So in our system, 
which is relatively free of those agents, we observed a differential effect. Thus, we 
can conclude that in our study, pravastatin fails to prevent the direct effect of aPL on 
the placenta and trophoblast function.  
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Finally, our findings demonstrate that, in vitro, pravastatin does not prevent the 
effects of anti-2GPI Abs on human first trimester trophoblast cell function and, 
therefore, may not be beneficial as a therapeutic for pregnant APS patients. Though 
there is a study in the mouse model of APS showing reduced miscarriage rates due 
to pravastatin treatment, whether pravastatin can prevent aPL-associated late-term 
pregnancy complications is unclear at this time because this efficacy is yet to be 
reproduced in other studies; and prior to our study, there was no study testing 
pravastatin in human APS model. Additionally, though the litters produced in the 
mouse model after treatment with pravastatin appeared normal, we do not yet 
know the long-term effects of this treatment on the off-spring. So more studies are 
needed to address these issues and determine the effectiveness of pravastatin in the 
prevention of aPL-associated pregnancy complications in humans. In the current 
state of care of APS patients, there is use of heparin and/or aspirin, which while 
they do not prevent late term complications, they are non-teratogens and to some 
extent do significantly reduce miscarriages. So while current research aims to 
improve treatment options in APS, at this point the risk of using pravastatin, a 
potential teratogen, outweighs its benefit in APS.  In contrast to APS, there is more 
data that can be viewed as support of the benefit of pravastatin in models of 
preeclampsia. However, while there is abnormal placentation in both classical 
preeclampsia and APS, it is worth noting that both are separate entities with 
different underlying mechanisms; therefore efficacy of pravastatin in classical 
preeclampsia may not directly translate into efficacy for preeclamptic APS patients.  
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In summary, this research study has demonstrated that pravastatin augments the 
aPL-induced inflammation and anti-angiogenic profile in the first trimester 
trophoblast cell line, but has no effect on aPL-induced responses in primary 
trophoblast cells. These findings demonstrate that pravastatin does not prevent the 
effects of aPL antibody on first trimester trophoblast cell function, and so may not be 
beneficial as a therapeutic for pregnant APS patients. However, with respect to the 
normal functions of the primary human first trimester trophoblast cell, particularly 
their innate ability to migrate, produce cytokines necessary for its function (such as 
IL 6), and produce angiogenic factors under resting, basal conditions, our study did 
not reveal any overt negative effects of pravastatin. With this finding and the fact 
that certain studies have illustrated its benefits in preeclampsia, independent of aPL 
[32, 33, 34], one might argue that pravastatin might be considered for use in non-
APS patients at high risk for preeclampsia. While studies suggest that this could be a 
beneficial option in preeclampsia, the risk of fetal anomaly with statin use still 
remains a significant possible adverse outcome. Therefore, since delivery of the 
placenta is a definitive treatment for preeclampsia, and in many cases can be 
accomplished without dangers of the lifetime sequel of prematurity, it may be 
worthwhile to follow that route for mild to moderate preeclampsia. Pravastatin use 
can then be reserved for the few cases of severe preeclampsia where the fetus is 
significantly premature and delivery would place the fetus at high risk of lifetime 
complications of prematurity. Further, even in such cases, it is difficult to 
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extrapolate, from our study, the appropriate dose that would be required for 
treatment of preeclampsia since the only documented use of statins in pregnancy is 
old literature about inadvertent use for treatment of hyperlipidemia. Also, unlike in 
our studies, statins are typically clinically dosed on a fixed milligram amount 
regardless of patient weight. Additionally though not well studied at this point, the 
physiology of pregnancy could alter the pharmacokinetics of pravastatin and such 
changes may not be fully captured in in vitro studies like ours.  Therefore more 
studies, such as the on-going randomized controlled clinical trial [65] would provide 
such helpful information. Meanwhile, there are limited in vivo studies using 
pravastatin to prevent aPL-mediated pregnancy complications and so more research 
is needed in that area. Future studies by us will be directed towards elucidating the 
mechanism through which pravastatin augments aPL-mediated responses in the cell 
line.  
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